Literature DB >> 66985

Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice.

F Orsini, Z Pavelic, E Mihich.   

Abstract

Spleen cell populations from mice treated with Adriamycin or daunorubicin were found to develop a greater complement-independent cellular cytotoxic immune response during culture with allogeneic tumor cells than spleen cells from untreated or cyclophosphamide-treated animals. A temporal and drug dose dependence of this effect was demonstrated. The changes in spleen cell population occurring in the donor mice consequent to drug treatment were evident in the nylon woll-adherent fraction of the spleen cells. The results are consistent with the possibility that the concentration of specific progenitor or accessory cells in the spleen is increased consequent to drug treatment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 66985

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Resistance to cytotoxic chemotherapy is induced by NK cells in non-Hodgkin's Lymphoma Cells.

Authors:  Daeho Cho; Young-In Kim; Jae Seung Kang; Eunsil Hahm; Yoolhee Yang; Daejin Kim; Seonghan Kim; Yeong Seok Kim; Daeyoung Hur; Hyunjeong Park; Young Il Hwang; Tae-Sung Kim; Wang Jae Lee
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

2.  A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Premal H Thaker; William E Brady; Heather A Lankes; Kunle Odunsi; William H Bradley; Kathleen N Moore; Carolyn Y Muller; Khursheed Anwer; Russell J Schilder; Ronald D Alvarez; Paula M Fracasso
Journal:  Gynecol Oncol       Date:  2017-08-10       Impact factor: 5.482

3.  Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity.

Authors:  Stefano Di Biase; Changhan Lee; Sebastian Brandhorst; Brianna Manes; Roberta Buono; Chia-Wei Cheng; Mafalda Cacciottolo; Alejandro Martin-Montalvo; Rafael de Cabo; Min Wei; Todd E Morgan; Valter D Longo
Journal:  Cancer Cell       Date:  2016-07-11       Impact factor: 31.743

4.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

5.  Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions.

Authors:  D L Maccubbin; S A Cohen; M J Ehrke
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 6.  Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Authors:  James L Gulley; Ravi A Madan; Philip M Arlen
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

7.  Modulation of antitumoral antibody-dependent cellular cytotoxicity and natural killer activity by Adriamycin and daunorubicin.

Authors:  R W Pfeifer; H B Bosmann
Journal:  Agents Actions       Date:  1982-12

8.  Cytochalasin-B-induced immunosuppression of murine allogeneic anti-tumor response and the effect of recombinant human interleukin-2.

Authors:  D Bogyo; S R Fondy; L Finster; C Fondy; S Patil; T P Fondy
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Cytolytic T lymphocytes and antibodies to myocytes in adriamycin-treated BALB/c mice. Evidence for immunity to drug-induced antigens.

Authors:  S A Huber; A Moraska
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

10.  A trial of postoperative adjuvant combination chemo-immunotherapy for stage IV gastric carcinoma.

Authors:  T Akiyoshi; S Arinaga; K Takamuku; T Wada; F Koba; H Tsuji
Journal:  Jpn J Surg       Date:  1988-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.